https://www.mdpi.com/1999-4915/13/2/271/htm (th
Post# of 72447
(Total Views: 589)
Posted On: 11/10/2021 3:07:45 AM
https://www.mdpi.com/1999-4915/13/2/271/htm
(this is the Full Text version)
By combining remdesivir with brilacidin, a two-pronged strategy of inhibiting viral entry and viral RNA synthesis might be successfully leveraged to most effectively control progression of SARS-CoV-2 infection. The opportunity that combination treatments with brilacidin could potentially offer in treating COVID-19 requires further exploration, and in vivo animal studies are in planning stages.
Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control both viral load and the corresponding inflammatory damage due to SARS-CoV-2 [72], and mitigate bacterial coinfections. With its HDP mimetic properties—antiviral, immuno/anti-inflammatory, and antibacterial—brilacidin may be able to address the different disease parameters of COVID-19 within the one therapeutic treatment. The results of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in addition to standard of care, are highly anticipated.
In this manuscript, we demonstrate brilacidin exhibits robust inhibition of SARS-CoV-2 in Vero cells and Calu-3 cells, and in two strains of the virus. Likely to function as a viral entry inhibitor [73,74,75], the proposed mechanism of action for brilacidin includes affecting the integrity of the viral membrane and interfering with viral entry. Brilacidin also exhibited an excellent synergistic inhibitory profile against SARS-CoV-2 in combination with remdesivir. Destabilizing viral integrity is a desirable antiviral property, especially in relation to pan-coronavirus agents, as the viral membrane is highly conserved and similar in construct across different coronavirus strains. Further research will be conducted in the context of other lethal coronaviruses (MERS-CoV, SARS-CoV) toward assessing the potential of brilacidin as a broad-spectrum inhibitor of coronaviruses.
As we await the P-2 trial data UNLOCK any day now..its hard not to imagine where we go if we get + results. I believe the 5 day course vs the earlier 3 days course will show stat improvement and the comp to a possible FUTURE STUDY w/ Rem looking at potential synergy is likely..the reason being is REM is the only approved Tx for seriously ill patients who are Hospitalized...the door is open on SYNERGY EVALUATION..I dont see a Comp trial coming but I do see a FU SYNERGY trial coming very soon where BRIL is added to REM vs REM alone. Clinically proved SYNERGY and better outcomes in a combo of REM + BRIL is a GOLDMINE oppy....than Bingo GILD will make the ACQ play..they are cash rich and BRIL is right in their VIRAL WHEELHOUSE...a + study soon gets our Share Price to God knows where but at least $1 to maybe $10..who knows..but as a former Pharma guy I know Big Pharmas have a hard time selling penny stk to their BODs....so a better priced IPIX say $5-10/share value would with its MC at say $2B plus is lots more APPEALING to a BOD...but a penny stk on an OTC BB is not... so a possible RS may be in the works very soon after the data lock data is released...say 400M shs to 40M or 1:10..again that would take IPIX up to $50/share val from a $5 otc bb sp but now we get onto NASDAQ w/ lots of cash and share stabilty in a big tradable nasdaq moat..
I can see an offer of 50% Premium for everything so a post RS IPIX worth $50 at 40M shares could fetch $75 or more imo...I like that many other virus seem to be susceptible to BRIL as well including HSV and HIV, and Zika and common cold virus is simply HUGE....keep in mind that we never got a HIV vaccine, and FAUCI et al have poured BILLIONS into it since 1981 and BRIL could be very helpful in a cocktail w/ currect Txs...look at HepV/B today as the new Tx's are CURATIVE in just a couple of months therapy!
Lots to be happy about here..lots more IF we get + news!
RP
(this is the Full Text version)
By combining remdesivir with brilacidin, a two-pronged strategy of inhibiting viral entry and viral RNA synthesis might be successfully leveraged to most effectively control progression of SARS-CoV-2 infection. The opportunity that combination treatments with brilacidin could potentially offer in treating COVID-19 requires further exploration, and in vivo animal studies are in planning stages.
Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control both viral load and the corresponding inflammatory damage due to SARS-CoV-2 [72], and mitigate bacterial coinfections. With its HDP mimetic properties—antiviral, immuno/anti-inflammatory, and antibacterial—brilacidin may be able to address the different disease parameters of COVID-19 within the one therapeutic treatment. The results of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in addition to standard of care, are highly anticipated.
In this manuscript, we demonstrate brilacidin exhibits robust inhibition of SARS-CoV-2 in Vero cells and Calu-3 cells, and in two strains of the virus. Likely to function as a viral entry inhibitor [73,74,75], the proposed mechanism of action for brilacidin includes affecting the integrity of the viral membrane and interfering with viral entry. Brilacidin also exhibited an excellent synergistic inhibitory profile against SARS-CoV-2 in combination with remdesivir. Destabilizing viral integrity is a desirable antiviral property, especially in relation to pan-coronavirus agents, as the viral membrane is highly conserved and similar in construct across different coronavirus strains. Further research will be conducted in the context of other lethal coronaviruses (MERS-CoV, SARS-CoV) toward assessing the potential of brilacidin as a broad-spectrum inhibitor of coronaviruses.
As we await the P-2 trial data UNLOCK any day now..its hard not to imagine where we go if we get + results. I believe the 5 day course vs the earlier 3 days course will show stat improvement and the comp to a possible FUTURE STUDY w/ Rem looking at potential synergy is likely..the reason being is REM is the only approved Tx for seriously ill patients who are Hospitalized...the door is open on SYNERGY EVALUATION..I dont see a Comp trial coming but I do see a FU SYNERGY trial coming very soon where BRIL is added to REM vs REM alone. Clinically proved SYNERGY and better outcomes in a combo of REM + BRIL is a GOLDMINE oppy....than Bingo GILD will make the ACQ play..they are cash rich and BRIL is right in their VIRAL WHEELHOUSE...a + study soon gets our Share Price to God knows where but at least $1 to maybe $10..who knows..but as a former Pharma guy I know Big Pharmas have a hard time selling penny stk to their BODs....so a better priced IPIX say $5-10/share value would with its MC at say $2B plus is lots more APPEALING to a BOD...but a penny stk on an OTC BB is not... so a possible RS may be in the works very soon after the data lock data is released...say 400M shs to 40M or 1:10..again that would take IPIX up to $50/share val from a $5 otc bb sp but now we get onto NASDAQ w/ lots of cash and share stabilty in a big tradable nasdaq moat..
I can see an offer of 50% Premium for everything so a post RS IPIX worth $50 at 40M shares could fetch $75 or more imo...I like that many other virus seem to be susceptible to BRIL as well including HSV and HIV, and Zika and common cold virus is simply HUGE....keep in mind that we never got a HIV vaccine, and FAUCI et al have poured BILLIONS into it since 1981 and BRIL could be very helpful in a cocktail w/ currect Txs...look at HepV/B today as the new Tx's are CURATIVE in just a couple of months therapy!
Lots to be happy about here..lots more IF we get + news!
RP
(4)
(0)